Editorial Comment to Docetaxel‐based chemotherapy combined with dexamethasone 1 mg daily oral administration for castration‐resistant prostate cancer: Long‐term outcomes

Takeshi Yuasa

doi:10.1111/iju.14018

Editorial Comment to Docetaxel‐based chemotherapy combined with dexamethasone 1 mg daily oral administration for castration‐resistant prostate cancer: Long‐term outcomes

International Journal of Urology ◽

10.1111/iju.14018 ◽

2019 ◽

Vol 26 (8) ◽

pp. 803-803

Author(s):

Takeshi Yuasa

Keyword(s):

Prostate Cancer ◽

Editorial Comment ◽

Oral Administration ◽

Castration Resistant Prostate Cancer ◽

Long Term Outcomes ◽

Castration Resistant ◽

Daily Oral Administration

Download Full-text

Docetaxel‐based chemotherapy combined with dexamethasone 1 mg daily oral administration for castration‐resistant prostate cancer: Long‐term outcomes

International Journal of Urology ◽

10.1111/iju.14009 ◽

2019 ◽

Vol 26 (8) ◽

pp. 797-803 ◽

Cited By ~ 4

Author(s):

Nobumichi Tanaka ◽

Kazuo Nishimura ◽

Eijiro Okajima ◽

Kenji Ina ◽

Osamu Ogawa ◽

...

Keyword(s):

Prostate Cancer ◽

Oral Administration ◽

Castration Resistant Prostate Cancer ◽

Long Term Outcomes ◽

Castration Resistant ◽

Daily Oral Administration

Download Full-text

Long-term outcomes of definitive external-beam radiotherapy for non-metastatic castration-resistant prostate cancer

International Journal of Clinical Oncology ◽

10.1007/s10147-018-1265-8 ◽

2018 ◽

Vol 23 (4) ◽

pp. 749-756 ◽

Cited By ~ 2

Author(s):

Rihito Aizawa ◽

Kenji Takayama ◽

Kiyonao Nakamura ◽

Takahiro Inoue ◽

Takashi Kobayashi ◽

...

Keyword(s):

Prostate Cancer ◽

External Beam Radiotherapy ◽

External Beam ◽

Castration Resistant Prostate Cancer ◽

Long Term Outcomes ◽

Castration Resistant

Download Full-text

Response to Editorial Comment to Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital

International Journal of Urology ◽

10.1111/iju.13861 ◽

2018 ◽

Vol 25 (12) ◽

pp. 1005-1005 ◽

Cited By ~ 1

Author(s):

Devin N Patel ◽

Brian F Chapin ◽

Stephen J Freedland

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Editorial Comment ◽

Local Therapy ◽

Equal Access ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Cancer Hospital

Download Full-text

Mortality in men with castration‐resistant prostate cancer—A long‐term follow‐up of a population‐based real‐world cohort

BJUI Compass ◽

10.1002/bco2.116 ◽

2021 ◽

Author(s):

Yashar Khoshkar ◽

Marcus Westerberg ◽

Jan Adolfsson ◽

Anna Bill‐Axelson ◽

Henrik Olsson ◽

...

Keyword(s):

Prostate Cancer ◽

Real World ◽

Population Based ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Long Term Follow Up

Download Full-text

Long-Term Androgen Ablation and Docetaxel Up-Regulate Phosphorylated Akt in Castration Resistant Prostate Cancer

The Journal of Urology ◽

10.1016/j.juro.2011.02.016 ◽

2011 ◽

Vol 185 (6) ◽

pp. 2376-2381 ◽

Cited By ~ 26

Author(s):

Takeo Kosaka ◽

Akira Miyajima ◽

Suguru Shirotake ◽

Eriko Suzuki ◽

Eiji Kikuchi ◽

...

Keyword(s):

Prostate Cancer ◽

Castration Resistant Prostate Cancer ◽

Androgen Ablation ◽

Castration Resistant ◽

Phosphorylated Akt

Download Full-text

Re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032

European Urology ◽

10.1016/j.eururo.2020.09.049 ◽

2021 ◽

Vol 79 (1) ◽

pp. e10-e11

Author(s):

Ethan B. Ludmir ◽

Zachary R. McCaw ◽

Lee-Jen Wei

Keyword(s):

Prostate Cancer ◽

Final Analysis ◽

Phase Iii ◽

Castration Resistant Prostate Cancer ◽

Phase Iii Trial ◽

Castration Resistant ◽

Long Term Survivors

Download Full-text

Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer

European Urology ◽

10.1016/j.eururo.2016.02.035 ◽

2016 ◽

Vol 70 (3) ◽

pp. 438-444 ◽

Cited By ~ 24

Author(s):

Karim Fizazi ◽

Kim N. Chi ◽

Johann S. de Bono ◽

Leonard G. Gomella ◽

Kurt Miller ◽

...

Keyword(s):

Prostate Cancer ◽

Adverse Events ◽

Low Dose ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Low Incidence ◽

Dose Prednisone

Download Full-text

Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel

Cancer Management and Research ◽

10.2147/cmar.s41667 ◽

2013 ◽

pp. 25 ◽

Cited By ~ 13

Author(s):

John Araujo ◽

Trudel ◽

Paliwal

Keyword(s):

Prostate Cancer ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant

Download Full-text

Editorial Comment to High neutrophil-to-lymphocyte ratio predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy

International Journal of Urology ◽

10.1111/iju.12856 ◽

2015 ◽

Vol 22 (9) ◽

pp. 834-834

Author(s):

Robert J van Soest

Keyword(s):

Prostate Cancer ◽

Clinical Outcome ◽

Editorial Comment ◽

Neutrophil To Lymphocyte Ratio ◽

Castration Resistant Prostate Cancer ◽

Poor Clinical Outcome ◽

Lymphocyte Ratio ◽

Castration Resistant ◽

Docetaxel Chemotherapy

Download Full-text

P124 Long-term safety of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase 3 ALSYMPCA study

European Urology Supplements ◽

10.1016/s1569-9056(13)62445-8 ◽

2013 ◽

Vol 12 (6) ◽

pp. 178

Author(s):

S Nilsson ◽

A.J. Schrader ◽

J. Kliment ◽

A. Solberg ◽

L. Franzén ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Castration Resistant Prostate Cancer ◽

Phase 3 ◽

Castration Resistant ◽

Radium 223

Download Full-text